Premium
FOXE1 is a target for aberrant methylation in cutaneous squamous cell carcinoma
Author(s) -
Venza I.,
Visalli M.,
Tripodo B.,
De Grazia G.,
Loddo S.,
Teti D.,
Venza M.
Publication year - 2010
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2009.09560.x
Subject(s) - demethylating agent , carcinogenesis , epigenetics , methylation , dna methylation , cancer research , biology , medicine , cancer , microbiology and biotechnology , gene expression , gene , genetics
Summary Background Several cancer‐related genes are silenced by promoter hypermethylation in skin cancers. However, to date the somatic epigenetic events that occur in cutaneous squamous cell carcinoma (SCC) tumorigenesis have not been well defined. Objectives To examine epigenetic abnormalities of FOXE1 , a gene located on chromosome 9q22, a region frequently lost in SCC. Methods We investigated the methylation status of FOXE1 in 60 cases of cutaneous SCC by methylation‐specific polymerase chain reaction, and comparatively examined mRNA and protein expression by real‐time polymerase chain reaction and Western blot, respectively. Results We found a higher frequency of FOXE1 promoter hypermethylation in SCCs (55%), as compared with the adjacent uninvolved skin (12%) and blood control samples (9·5%). FOXE1 methylation was frequently seen in association with a complete absence of or downregulated gene expression. Treatment with the demethylating agent 5‐Aza‐2′‐deoxycytidine resulted in profound reactivation of FOXE1 expression. Conclusions These results indicate that FOXE1 is a crucial player in development of cutaneous SCC.